- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07442877
En fas 2 klinisk prövning som utvärderar effektiviteten och säkerheten hos HSK21542 för patienter med postoperativ smärtbehandling vid ortopedisk kirurgi
En multicenter, randomiserad, dubbelblind, placebokontrollerad/aktivkontrollerad fas II-klinisk studie för att utvärdera effektiviteten och säkerheten för HSK21542-injektion vid behandling av postoperativ smärta vid ortopedisk kirurgi
This is a multi-center, randomized, double-blind, placebo/active-controlled study. 160 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Chongqing, Kina
- The Second Affiliated Hospital of Chongqing Medical University
-
Shanghai, Kina
- Huashan Hospital, Fudan University
-
Shenzhen, Kina
- Shenzhen Second People's Hospital
-
-
Anhui
-
Hefei, Anhui, Kina
- The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- The Third Affiliated Hospital, Southern Medical University
-
-
Guangxi
-
Liuzhou, Guangxi, Kina
- Liuzhou People's Hospital
-
-
Hebei
-
Cangzhou, Hebei, Kina
- Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine
-
Shijiazhuang, Hebei, Kina
- The Third Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, Kina
- The First Hospital of Hebei Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina
- The Fourth Affiliated Hospital of Harbin Medical University
-
Harbin, Heilongjiang, Kina
- The Second Affiliated Hospital of Harbin Medical University
-
-
Hubei
-
Yichang, Hubei, Kina
- Yichang Central People's Hospital (Wujia Campus)
-
Yichang, Hubei, Kina
- Yichang Central People's Hospital (Xiling Campus)
-
-
Hunan
-
Changsha, Hunan, Kina
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, Kina
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Huaian, Jiangsu, Kina
- Huai'an Second People's Hospital
-
Nanjing, Jiangsu, Kina
- Nanjing First Hospital
-
Nanjing, Jiangsu, Kina
- Zhongda Hospital, Southeast University
-
Wuxi, Jiangsu, Kina
- Wuxi People's Hospital
-
-
Jiangxi
-
Ganzhou, Jiangxi, Kina
- Ganzhou People's Hospital
-
-
Shandong
-
Jinan, Shandong, Kina
- The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
-
-
Sichuan
-
Mianyang, Sichuan, Kina
- Mianyang Central Hospital
-
Mianyang, Sichuan, Kina
- Mianyang Orthopedic Hospital
-
Suining, Sichuan, Kina
- Suining Central Hospital
-
-
Zhejiang
-
Huzhou, Zhejiang, Kina
- Huzhou Central Hospital
-
Jinhua, Zhejiang, Kina
- Jinhua Central Hospital
-
Wenzhou, Zhejiang, Kina
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18 years old ≤ age ≤74 years old, regardless of gender;
- 18 kg/m2≤BMI≤32 kg/m2, meet the weight range specified in the protocol;
- American Society of Anesthesiologists (ASA) grade 1-3;
- Accept hip replacement under general anesthesia;
- Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
- Fully understand and voluntarily participate this trial, and sign the informed consent form;
Exclusion Criteria:
- Patients with allergy to opioids or any component of the trial drug;
- Patients with a history of severe cardiovascular and cerebrovascular diseases, ,and psychiatric disorders;
- Last use of opioid or non-opioid analgesics less than 5 half-lives or the duration of drug efficacy prior to randomization; use of drugs with unclear half-lives that may affect analgesic efficacy within 7 days prior to randomization, or last use of drugs affecting analgesic efficacy less than 5 half-lives prior to randomization, as well as Chinese herbal medicines or proprietary Chinese medicines deemed by the investigator as potentially impacting the evaluation of efficacy and safety;
- Continuous use of opioid analgesics for more than 7 days for any reason within 30 days prior to screening;
- Laboratory test results during the screening period meeting any of the following criteria: 1) Significantly abnormal hematology results; 2) Significantly abnormal prothrombin time test results; 3) Significantly abnormal liver or kidney function; 4) Significantly abnormal fasting blood glucose;
- Positive test results during the screening period for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody;
- A history of drug, drug, and/or alcohol abuse
- Participate in any clinical trail within 30 days;
- Pregnant or lactating female subjects;
- Subjects of childbearing potential who are unwilling to use contraception throughout the study period or plan to become pregnant within 3 months after the study.
- Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HSK21542 dose level 1
Patients administrated with HSK21542 dose level 1 |
Patients administrated with HSK21542 dose level 1 |
|
Experimentell: HSK21542 dose level 2
Patients administrated with HSK21542 dose level 2 |
Patients administrated with HSK21542 dose level 2 |
|
Placebo-jämförare: Placebo control
Patients administrated with placebo |
Patients administrated with placebo |
|
Aktiv komparator: Actice control
Patients administrated with morphine |
Patients administrated with morphine |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sum of Pain Intensity Differences (SPID)
Tidsram: 48 hours
|
Sum of Pain Intensity Differences (SPID) of each group |
48 hours
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sum of Pain Intensity Differences (SPID) in other time frame
Tidsram: 0-8 hours, 0-24 hours, 24-48 hours
|
Sum of Pain Intensity Differences (SPID) in other time frame |
0-8 hours, 0-24 hours, 24-48 hours
|
|
Number of times rescue analgesic medications were administered.
Tidsram: 48 hours
|
Number of times rescue analgesic medications were administered. |
48 hours
|
|
Total morphine consumption
Tidsram: 48 hours
|
Total morphine consumption of each group |
48 hours
|
|
Proportion of subjects experiencing nausea and/or vomit
Tidsram: 48 hours
|
Proportion of subjects experiencing nausea and/or vomit of each group |
48 hours
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HSK21542-209
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .